Ryan J Ellis, Cary Jo R Schlick, Joe Feinglass, Mary F Mulcahy, Al B Benson, Sheetal M Kircher, Tony D Yang, David D Odell, Karl Bilimoria, Ryan P Merkow
{"title":"Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot?","authors":"Ryan J Ellis, Cary Jo R Schlick, Joe Feinglass, Mary F Mulcahy, Al B Benson, Sheetal M Kircher, Tony D Yang, David D Odell, Karl Bilimoria, Ryan P Merkow","doi":"10.1136/bmjqs-2019-009742","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy quality measures consider hospitals compliant when chemotherapy is recommended, even if it is not received. This may mask shortcomings in cancer care delivery. Objectives of this study were to (1) identify patient factors associated with failure to receive recommended chemotherapy without a documented contraindication and (2) assess hospital variation in failure to administer recommended chemotherapy.</p><p><strong>Methods: </strong>Patients from 2005 to 2015 with breast, colon and lung cancers who failed to receive recommended chemotherapy were identified using the National Cancer Database. Hospital-level rates of failure to administer recommended chemotherapy were calculated, and patient and hospital factors associated with failure to receive recommended chemotherapy were identified by multivariable logistic regression.</p><p><strong>Results: </strong>A total of 183 148 patients at 1281 hospitals were analysed. Overall, 3.5% of patients with breast, 6.6% with colon and 10.7% with lung cancers failed to receive recommended chemotherapy. Patients were less likely to receive recommended chemotherapy in all cancers if uninsured or on Medicaid (p<0.05), as were non-Hispanic black patients with both breast and colon cancer (p<0.001). Significant hospital variation was observed, with hospital-level rates of failure to administer recommended chemotherapy as high as 21.8% in breast, 40.2% in colon and 40.0% in lung cancers.</p><p><strong>Conclusions and relevance: </strong>Though overall rates are low, failure to receive recommended chemotherapy is associated with sociodemographic factors. Hospital variation in failure to administer recommended chemotherapy is masked by current quality measure definitions and may define a significant and unmeasured difference in hospital quality.</p>","PeriodicalId":49653,"journal":{"name":"Quality & Safety in Health Care","volume":"29 1","pages":"103-112"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382916/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quality & Safety in Health Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjqs-2019-009742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chemotherapy quality measures consider hospitals compliant when chemotherapy is recommended, even if it is not received. This may mask shortcomings in cancer care delivery. Objectives of this study were to (1) identify patient factors associated with failure to receive recommended chemotherapy without a documented contraindication and (2) assess hospital variation in failure to administer recommended chemotherapy.
Methods: Patients from 2005 to 2015 with breast, colon and lung cancers who failed to receive recommended chemotherapy were identified using the National Cancer Database. Hospital-level rates of failure to administer recommended chemotherapy were calculated, and patient and hospital factors associated with failure to receive recommended chemotherapy were identified by multivariable logistic regression.
Results: A total of 183 148 patients at 1281 hospitals were analysed. Overall, 3.5% of patients with breast, 6.6% with colon and 10.7% with lung cancers failed to receive recommended chemotherapy. Patients were less likely to receive recommended chemotherapy in all cancers if uninsured or on Medicaid (p<0.05), as were non-Hispanic black patients with both breast and colon cancer (p<0.001). Significant hospital variation was observed, with hospital-level rates of failure to administer recommended chemotherapy as high as 21.8% in breast, 40.2% in colon and 40.0% in lung cancers.
Conclusions and relevance: Though overall rates are low, failure to receive recommended chemotherapy is associated with sociodemographic factors. Hospital variation in failure to administer recommended chemotherapy is masked by current quality measure definitions and may define a significant and unmeasured difference in hospital quality.
背景:化疗质量指标考虑了医院在推荐化疗时的依从性,即使化疗没有被接受。这可能掩盖了癌症护理服务的不足。本研究的目的是:(1)确定患者在没有禁忌症的情况下未能接受推荐化疗的相关因素;(2)评估医院在未能实施推荐化疗方面的差异。方法使用美国国家癌症数据库(National Cancer Database)对2005年至2015年未接受推荐化疗的乳腺癌、结肠癌和肺癌患者进行筛选。计算医院一级推荐化疗失败率,并通过多变量logistic回归确定与推荐化疗失败相关的患者和医院因素。结果共对1281家医院的183148例患者进行分析。总体而言,3.5%的乳腺癌患者、6.6%的结肠癌患者和10.7%的肺癌患者未能接受推荐的化疗。没有医疗保险或有医疗补助的患者接受推荐化疗的可能性较低(p<0.05),同时患有乳腺癌和结肠癌的非西班牙裔黑人患者也是如此(p<0.001)。观察到显著的医院差异,医院级别的化疗失败率在乳腺癌中高达21.8%,结肠癌中高达40.2%,肺癌中高达40.0%。结论和相关性虽然总体失败率很低,但未能接受推荐的化疗与社会人口因素有关。目前的质量测量定义掩盖了未能实施推荐化疗的医院差异,并可能定义了医院质量的显著和不可测量的差异。